Clinical Trial Update: Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and tolerability of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia or relapsed or refr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CC-91633 (BMS-986397) (BMS-986397)

Snippet

Sponsor: Celgene | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED